Aims: To compare the clinical utility of contrast enhanced magnetic resonance imaging (MRI) to ultrasound (USS) and computed tomography (CT) in focal hepatic lesions (FHLs)
Methods: This retrospective study analysed 125 consecutive iron oxide enhanced (SPIO) MRI.
Results: MRI made a difference in 74% of patients who had USS and in 42% of patients who had a CT scan. In suspected cancer, MRI changed diagnosis in 58% and 37% (13/35), respectively.
Conclusions: MRI is superior to other noninvasive imaging modalities for lesion identification and characterisation.